The company is recalling lot number T04769, which might be in cartons labeled for dronabinol capsules 2.5 milligram — a drug for nausea and anorexia associated with weight loss in AIDS patients — or in packages labeled for ziprasidone hydrochloride capsules 20 milligram — a schizophrenia medication.
“There is a reasonable probability that patients who mistakenly take [dronabinol] instead of [ziprasidone] can experience serious adverse events from missing their ziprasidone dose and taking an unexpected dose of dronabinol,” the FDA said June 14. “Patients missing doses of ziprasidone can experience exacerbation of underlying health issues such as bipolar disorder, schizophrenia, agitation, aggression or delirium. This can result in mental illness instability with possible consequences of self-harm or harm to others which could result in medical or psychiatric hospitalization.”
No adverse events have been reported.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
